Suicidal Behavior and Severe Neuropsychiatric Disorders Following Glucocorticoid Therapy in Primary Care
The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: The incidence and the risk of suicidal behaviors and severe neuropsychiatric disorders in people treated with systemic glucocorticoids are poorly known. The authors assessed the incidence rates of depression, mania, delirium, panic disorder, and suicidal behaviors in patients treated with glucocorticoids in primary care settings and the risk factors for developing these outcomes. METHOD: Data were obtained for all adult patients registered between 1990 and 2008 at U.K. general practices contributing to The Health Improvement Network (THIN) primary care database. The incidence rates for the outcomes of interest were assessed in patients who received prescriptions for oral glucocorticoids and compared with those in patients who did not receive such prescriptions. The predictors of these outcomes in exposed patients were ascertained using Cox proportional hazards models. RESULTS: Overall, 786,868 courses of oral glucocorticoids were prescribed for 372,696 patients. The authors identified 109 incident cases of suicide or suicide attempt and 10,220 incident cases of severe neuropsychiatric disorders in these patients. The incidence of any of these outcomes was 22.2 per 100 person-years at risk for first-course treatments. Compared to people with the same underlying medical disease who were not treated with glucocorticoids, the hazard ratio for suicide or suicide attempt in exposed patients was 6.89 (95% CI=4.52–10.50); for depression, 1.83 (95% CI=1.72–1.94); for mania, 4.35 (95% CI=3.67–5.16); for delirium, confusion, or disorientation, 5.14 (95% CI=4.54–5.82); and for panic disorder, 1.45 (95% CI=1.15–1.85). Older men were at higher risk of delirium/confusion/disorientation and mania, while younger patients were at higher risk of suicide or suicide attempt. Patients with a previous history of neuropsychiatric disorders and those treated with higher dosages of glucocorticoids were at greater risk of neuropsychiatric outcomes. CONCLUSIONS: Glucocorticoids increase the risk of suicidal behavior and neuropsychiatric disorders. Educating patients and their families about these adverse events and increasing primary care physicians' awareness about their occurrence should facilitate early monitoring.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Two meta-analyses 64,65 concluded that cortisol levels in MDD were elevated, with a moderate effect size.”
From Major depressive disorder (2016) · cites this paper as [65]
Citations
Cites
Mechanisms involved in the side effects of glucocorticoids
SCHACKE, H. (2002) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(02)00297-8 · Cited by 1,847 · cited 1×
“Natural glucocorticoids such as cortisol affect behavior, mood, and other CNS-related processes (1).”
BackgroundDiagnosis and complications of Cushing’s syndrome: a consensus statement
Arnaldi, G., Angeli, A., Atkinson, A. B., Bertagna, X., Cavagnini, F., Chrousos, G. P., Fava, G. A., Findling, J. W., Gaillard, R. C., Grossman, A. B., et al. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030871 · Cited by 1,362
Validation and validity of diagnoses in the General Practice Research Database: a systematic review
Herrett, E., Thomas, S. L., Schoonen, W. M., Smeeth, L., & Hall, A. J. (2010) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2009.03537.x · Cited by 1,109
Psychiatric Adverse Effects of Corticosteroids
Warrington, T. P., & Bostwick, J. M. (2006) · Mayo Clinic Proceedings · doi:10.4065/81.10.1361 · Cited by 611
Lewis, J. D., Schinnar, R., Bilker, W. B., Wang, X., & Strom, B. L. (2007) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1335 · Cited by 602
Population‐based assessment of adverse events associated with long‐term glucocorticoid use
Curtis, J. R., Westfall, A. O., Allison, J., Bijlsma, J. W., Freeman, A., George, V., Kovac, S. H., Spettell, C. M., & Saag, K. G. (2006) · Arthritis Care & Research · doi:10.1002/art.21984 · Cited by 595
Use of oral corticosteroids in the United Kingdom
van Staa, T. P. (2000) · QJM · doi:10.1093/qjmed/93.2.105 · Cited by 529
Steroid-induced psychiatric syndromes
Lewis, D. A., & Smith, R. E. (1983) · Journal of Affective Disorders · doi:10.1016/0165-0327(83)90022-8 · Cited by 528
The Read clinical classification.
Chisholm, J. (1990) · BMJ · doi:10.1136/bmj.300.6732.1092 · Cited by 504
Walsh, L. J., Wong, C. A., Pringle, M., & Tattersfield, A. E. (1996) · BMJ · doi:10.1136/bmj.313.7053.344 · Cited by 383
Research works printed but not linked: 2
- CSD Medical Research/EPIC, 2007, THIN Data From EPIC: A Guide for Researchers
- Reckart MD, 1990, Int J Psychosom, 37, 57
Cited by
Otte, C., Gold, S. M., Penninx, B. W., Pariante, C. M., Etkin, A., Fava, M., Mohr, D. C., & Schatzberg, A. F. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.65 · Cited by 2,269
The Functional and Clinical Significance of the 24-Hour Rhythm of Circulating Glucocorticoids
Oster, H., Challet, E., Ott, V., Arvat, E., de Kloet, E. R., Dijk, D.-J., Lightman, S., Vgontzas, A., & Van Cauter, E. (2017) · Endocrine Reviews · doi:10.1210/er.2015-1080 · Cited by 548
Pruessner, M., Cullen, A. E., Aas, M., & Walker, E. F. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.12.013 · Cited by 315
Corticosteroid-related central nervous system side effects
Ciriaco, M., Ventrice, P., Russo, G., Scicchitano, M., Mazzitello, G., Scicchitano, F., & Russo, E. (2013) · Journal of Pharmacology and Pharmacotherapeutics · doi:10.4103/0976-500x.120975 · Cited by 244
“[13] In particular, in the CNS, glucocorticoids exert their potential effects at hippocampal level, a structure intimately involved in the limbic system, which provides the processing of emotional information and memory.[14] Various studies show a correlation between high levels of endogenous cortisol and hippocampal…”
Genomic and epigenomic mechanisms of glucocorticoids in the brain
Gray, J. D., Kogan, J. F., Marrocco, J., & McEwen, B. S. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2017.97 · Cited by 242
Metadata
- Authors
- Fardet, L., Petersen, I., & Nazareth, I.
- Affiliations
- The Royal Free Hospital (GB)
- Venue
- American Journal of Psychiatry
- Published
- 2012-05
- Volume
- 169
- Issue
- 5
- Pages
- 491-497
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W1972710070
- Semantic Scholar
- 685aae4b79751dcc2039c2233ce3afa9e737b047
- Cited by
- 287
- References
- 35
- Citations by year
- 2026: 12 · 2025: 14 · 2024: 18 · 2023: 20 · 2022: 20 · 2021: 30 · 2020: 25 · 2019: 9 · 2018: 40 · 2017: 18 · 2016: 23 · 2015: 15 · 2014: 21 · 2013: 13 · 2012: 7
- FWCI
- 20.28
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Journal of Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Suicide and Self-Harm Studies
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Keywords
- glucocorticoids, suicidal behavior, suicide attempts, neuropsychiatric disorders, depression, mania, delirium, panic disorder, adverse drug reactions, primary care, incidence, risk factors, glucocorticoid dose, older men, young men, patient education, adverse event monitoring, primary care prescribing, pharmacovigilance, antipsychotic prescribing
- MeSH terms
- Mental Disorders, Bipolar Disorder, Confusion, Delirium, Depression, Female, Glucocorticoids, United Kingdom, Humans, Male, Middle Aged, Primary Health Care, Risk Factors, Suicide, Suicide, Attempted, Proportional Hazards Models, Panic Disorder
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Suicidal Behavior and Severe Neuropsychiatric Disorders Following Glucocorticoid Therapy in Primary Care. https://app.cochat.ai/papers/10.1176/appi.ajp.2011.11071009
- The paper
- Fardet, L., Petersen, I., & Nazareth, I. (2012). Suicidal Behavior and Severe Neuropsychiatric Disorders Following Glucocorticoid Therapy in Primary Care. American Journal of Psychiatry. https://doi.org/10.1176/appi.ajp.2011.11071009
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.